[Resolution of the Joint Meeting of the Expert Council "Hypoparathyroidism in the Era of Complex Problems and Breakthrough Technologies"].

Authors

N G Mokrysheva, T P Bardymova, E E Bibik, A K Eremkina, T L Karonova, E V Kovaleva, I V Kryukova, I P Malaya, V A Peterkova, L S Sozaeva, M Sh Shamkhalova, T V Yakimova

Published in

Problemy endokrinologii. Volume 72. Issue 4. Pages 10-17. Sep 08, 2026. Epub Sep 08, 2026.

Abstract

On March 25, 2026, a meeting of the Expert Council entitled "Hypoparathyroidism in the Era of Complex Challenges and Breakthrough Technologies" was held in Moscow at the Endocrinology Research Centre. The meeting focused on the epidemiology of chronic hypoparathyroidism (hypoPT) in Russia, the specifics of patient management with this pathology in other countries, and the similarities and differences between international and Russian clinical guidelines.The meeting discussed advances in improving diagnostics and personalized treatment for patients with hypoPT in Russia, as well as the need to implement best practices in practical healthcare as part of the 2027 clinical guidelines revision.The importance of including chronic hypoPT in the official list of rare (orphan) diseases was highlighted, as was the need to continue studying the characteristics of the disease and its complications, diagnosis, monitoring, and prevention of hypoPT, including in the long term. The meeting also highlighted the relevance of an interdisciplinary professional alliance to achieve optimal treatment outcomes and improve the quality of life of patients with chronic hypoPT. The experts highlighted the need to implement innovative, effective treatment methods, including hormone replacement therapy for hypoPT. The Council discussed the efficacy and safety of the new therapeutic technology, TransCon parathyroid hormone. Invited expert Dilek Gogas Yavuz, MD, Professor at the Marmara University School of Medicine, Department of Endocrinology and Metabolism, Department of Internal Medicine (Istanbul, Turkey), shared her experience with the drug and the results of international clinical trials. This resolution is a summary of the issues discussed in the Council members' presentations and during the professional discussions.

PMID:
42733369
Bibliographic data and abstract were imported from PubMed on 14 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.